Incyte (INCY) cash flow statement

Biotechnology · NASDAQ · Health Care

$119.09 -0.98% Close Nov 17, 2026 Live

TrendArc score 53 of 100 · Health 7.0 · Momentum 6.0 · Moat 4.2 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

$1.4 billion

up 443.9% from the year before

Incyte generated $1.4 billion of free cash flow in the fiscal year to December 2025: $1.4 billion of cash from operations less $59 million of capital spending. That was 26.3% of revenue, against 5.9% the year before. Over the last four quarters, to September 30, 2026, it was $685 million.

What stands out

  • Free cash flow was 26.3% of revenue in the fiscal year to December 2025, 6th of 11 companies in Biotechnology on TrendArc.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

-$500M$500M$1.00B$1.50B2016201720182019202020212022202320242025$184MFree cash flow $1.35BNet income $1.29B-$500M$500M$1.00B$1.50B20172019202120232025Free cash flow $1.35BNet income $1.29B

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 1.41
  2. Capital spending -0.06
  3. Free cash flow 1.35
  4. Investments bought and sold, net -0.02
  5. Net share issuance 0.22
  6. Debt and other -0.15
  7. Net change in cash 1.41

In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In billions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income1.290.030.600.340.95-0.300.450.11-0.310.10
Depreciation and amortisation0.090.090.080.070.060.050.050.050.050.06
Stock-based pay0.260.250.270.220.190.180.180.170.150.130.10
Working capital and other items-0.22-0.05-0.400.37-0.44-0.060.040.020.030.05
Cash from operations0.741.410.340.500.970.75-0.120.710.34-0.090.30
Investing activities
Capital spending-0.06-0.06-0.09-0.03-0.08-0.18-0.19-0.08-0.07-0.11-0.12
Businesses bought and sold, net0.000.000.000.000.000.000.000.000.00-0.14
Investments bought and sold, net-0.020.26-0.160.00-0.03-0.08-0.01-0.01-0.240.03
Other investing-0.03-0.01-0.010.000.000.000.000.000.000.00
Cash from investing-0.100.16-0.21-0.08-0.21-0.27-0.09-0.09-0.35-0.23
Financing activities
Debt issued or repaid, net0.000.000.000.000.000.000.000.000.000.00
Shares issued less bought back0.460.22-1.960.040.060.060.130.080.030.720.05
Dividends paid0.000.000.000.000.000.000.000.000.000.000.00
Other financing-0.12-0.06-0.05-0.06-0.05-0.06-0.03-0.02-0.030.00
Cash from financing0.10-2.02-0.020.000.010.070.050.010.690.04
Net change in cash1.41-1.530.260.890.54-0.320.670.260.250.12
Free cash flow
Free cash flow0.681.350.250.460.890.57-0.310.630.26-0.200.18
Free cash flow margin11.4%26.3%5.9%12.6%26.3%19.0%-11.7%29.3%14.0%-13.3%16.7%
Free cash flow per share$6.75—$2.05$3.98$2.56-$1.43$2.91$1.22-$1.00$0.95
Free cash flow less stock-based pay1.11-0.020.250.700.39-0.490.470.11-0.340.09

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Incyte against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ExelixisEXEL Dec 2025$876M37.7%
RegeneronREGN Dec 2025$4.08B28.4%
Vertex PharmaceuticalsVRTX Dec 2025$3.19B26.6%
IncyteINCY Dec 2025$1.35B26.3%
BiogenBIIB Dec 2025$2.02B20.4%
Alnylam PharmaceuticalsALNY Dec 2025$465M12.5%
ModernaMRNA Dec 2025-$2.08B-106.7%
InsmedINSM Dec 2025-$968M-159.6%
Peer median20.4%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Incyte with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Incyte from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.